Dapagliflozin in Patients with Chronic Kidney Disease

The DAPA CKD trial evaluated the efficacy and safety of dapagliflozin, an SGLT2 inhibitor, in patients with chronic kidney disease (CKD), with or without type 2 diabetes. In this randomized, double blind, placebo controlled study involving 4304 participants, dapagliflozin significantly reduced the risk of the primary composite outcome (sustained decline in estimated GFR ≥50%, end stage kidney disease, or death from renal/cardiovascular causes) by 39% (HR 0.61; 95% CI, 0.51–0.72; P<0.001). Benefits extended to secondary outcomes, including cardiovascular death/hospitalization for heart failure (HR 0.71) and all cause mortality (HR 0.69). The safety profile was consistent with prior data, supporting dapagliflozin as a renoprotective therapy in CKD, irrespective of diabetes status.

The DAPA CKD trial evaluated the efficacy and safety of dapagliflozin, an SGLT2 inhibitor, in patients with chronic kidney disease (CKD), with or without type 2 diabetes. In this randomized, double blind, placebo controlled study involving 4304 participants, dapagliflozin significantly reduced the risk of the primary composite outcome (sustained decline in estimated GFR ≥50%, end stage kidney disease, or death from renal/cardiovascular causes) by 39% (HR 0.61; 95% CI, 0.51–0.72; P<0.001). Benefits extended to secondary outcomes, including cardiovascular death/hospitalization for heart failure (HR 0.71) and all cause mortality (HR 0.69). The safety profile was consistent with prior data, supporting dapagliflozin as a renoprotective therapy in CKD, irrespective of diabetes status.